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Surnrnm'y 
The transcription factor E2F is regulated during the cell cycle through interactions with the 
product of the retinoblastoma susceptibility gene and related proteins. It is thought that E2F- 
mediated gene regulation at the G1/S boundary and during S phase may be one of the rate- 
limiting steps in cell proliferation. It was reported that in vivo overexpression of E2F-1 in fi- 
hroblasts induces S phase entry and leads to apoptosis. This observation suggests  that E2F plays 
a role in both cell cycle regulation and apoptosis. To further understand the role of  E2F in cell 
cycle progression, cell death, and tumor development, we have blocked endogenous E2F ac- 
tivity in HBL-100 cells, derived from nonmalignant human breast epithelium, using dominant- 
negative mutants under the control of a tetracycline-dependent expression system. We have 
shown here that induction of dominant-negative mutants led to strong downregulation of tran- 
siently transfected E2F-dependent chloramphenicol acetyl transferase reporter constructs and of 
endogenous c-myc, which has been described as a target gene of the transcription factor E2F/ 
DP. In addition, we have shown that blocking of E2F could et~iciendy protect from apoptosis 
induced by serum starvation within a period of 10 d, whereas control cells started to die after 
24 h. Surprisingly, blocking of E2F did not alter the rate of proliferation or of DNA synthesis 
of these cells; this finding indicates that ceil-cycle progression could be driven in an E2F-inde- 
pendent manner. In addition, we have been able to show that blocking of endogenous E2F in 
HBL-100 cells led to rapid induction of tumor growth in severe combined immunodeficiency 
mice. No tumor growth could be observed in mice that received mock-transfected clones or 
tetracycline to block expression of  the E2F mutant constructs in vivo. Thus, it appears that E2F 
has a potential tumor-suppressive function under ce~ain circumstances. Furthermore, we pro- 
vide evidence that dysregulation of apoptosis may be an important step in tumorigenesis. 
A 
Poptosis and cell cycle are closely hnked and tightly 
regulated processes  that  control  tissue  development, 
differentiation, and  homeostasis  (1).  It is  well  established 
that deregulated expression and altered function of the genes 
involved in cell cycle regulation contribute to the patho- 
genesis of cancer (2). In the past few years, evidence accu- 
mulated that resistance toward apoptosis is another impor- 
tant factor for tumor development (3).  This has originally 
been shown in the case of B  cell malignancies (3-5). One 
important regulator ofapoptosis is the bd-2 oncogene, which 
was identified at t(14; 18) chromosomal translocation break- 
The first two authors contributed  equally  to this work. 
points in the majority of  follicular B cell lymphomas. These 
translocations  lead  to juxtaposition  of the  bd-2  gene  on 
chromosome 18, with the Ig heavy chain gene on chromo- 
some 14. Subsequent overexpression of  the bd-2 gene renders 
the lymphoma cells resistant to apoptosis. Thus dysregula- 
tion of apoptosis may be a causative event in the evolution 
of  B cell malignancies. 
The  tumor suppressor gene p53  exerts its  tumor-sup- 
pressing function by regulating both cell cycle and apopto- 
sis. Induction ofapoptosis by p53 is at least in part due to its 
ability to regulate transcription of  members of the bcl-2 gene 
family (6--8). Recently, we have shown that the death-pro- 
moting gene bax, another member of the bd-2 gene family, 
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dysregulation  of apoptosis might be not only an important 
step in the  development  of lymphoma but  also in the  de- 
velopment of solid tumors. 
Apoptosis  may  sustain  tissue  homeostasis  by  balancing 
the effects of proliferation. The regulatory coupling of pro- 
liferation and apoptosis is suggested by several recent find- 
ings.  A  line of investigation relevant to this hypothesis has 
focused on features shared by the pathways ofapoptosis and 
proliferation.  These studies have revealed that entry into S 
phase, an initial step in cell cycle progression, may also oc- 
cur  in  the  pathway  of cell  death  (10).  One  such  study  of 
prostate  epithelial  cells  showed  that  apoptosis  induced  by 
testosterone withdrawal is preceded by reentry into the cell 
cycle: after receiving a stimulus that induces apoptosis, qui- 
escent  prostate  epithelial  ceils  enter  S  phase  and  then  die 
without completing the ceil cycle. A second line of investi- 
gation  has  focused  on  regulatory  genes  that  control  both 
proliferation  and  apoptosis.  Expression  of genes important 
for cell cycle regulation,  including  cydin D, c-myc, Rb, and 
p53,  is associated not only with proliferation, but also with 
cell death (6, 11-13). E2F-1, the first member of the family 
of E2F transcription factors, is thought to play a critical role 
in G1/S progression of the  cell cycle (14-16).  E2F usually 
appears to function  to control the transcription  of a group 
of genes that encode proteins important for cell cycle pro- 
gression  during  S  phase;  these  proteins  include  dihydro- 
folate reductase,  thymidine kinase, and DNA polymerase ot 
(14). Transcriptional activities of E2F are modulated during 
the  ceil  cycle,  mainly by the  formation  of complexes be- 
tween E2F  and  several key regulators  of cell cycle such  as 
the  retinoblastoma  protein  and  related  proteins  (17-22). 
E2F-1  can form a heterodimer with another E2F-like pro- 
tien DP-1  and have a synergistic effect on its transcriptional 
activity (23, 24). Recently,  it has been shown that artificial 
overexpression of exogenous E2F-1  in fibroblasts promotes 
S phase entry and subsequently leads to apoptosis (25-28). 
It was the aim of this study to examine the role of E2F/ 
DP1  in apoptosis and cell cycle regulation. Using the tetra- 
cycline-dependent  expression  system,  we  established  ceil 
lines  containing  inducible  dominant-negative  DP-1  or 
E2F-2 mutants.  Our major findings are that (1) downregu- 
lation  of endogenous  E2F/DP  activity does  not  affect the 
proliferation rate in the breast epithelial cell line HBL-100 
but (2) leads to downregulation ofc-myc expression, (3) en- 
hanced resistance to apoptosis, and (4) induction  of tumor- 
igenic  growth  in  severe  combined  immunodeficiency 
(SCID) 1 mice. 
Materials and Methods 
Cells and Culture Conditions.  HBL-100 cells were originally iso- 
lated from breast milk of an apparently healthy woman (9). Cells 
were maintained in RPMI 1640  (Seromed-Biochrom, Hamburg, 
1Abbreviations used in this paper: CAT, chloramphenicol acetyl transferase; 
EMSA, electrophoretic mobility shift assay; GTC, guanidium isothiocyan- 
ate; RT, reverse transcription; SCID, severe combined immunodeficiency. 
Germany), 10% heat-inactivated  FCS, 2 mM L-glutamine (GIBCO, 
Karlsruhe, Germany) and penicillin--streptomycin (Seromed-Bio- 
chrom, Hamburg, Germany). 
Preparation of mRNA  and Reverse Transcription-PCR (RT-PCR). 
RNA preparation was performed using the guanidium isothiocy- 
anate  (GTC)/CsC1  method.  Briefly,  cells  or  tissue  were  lysed 
with GTC solution (4 M  GTC, 20 mM sodium acetate, pH 5.2, 
0.1 mM dithiothreitol, 0.5% Sarcosyl (Sigma Chemical Co., Griin- 
wald,  Germany). The resulting GTC-cell lysate  was layered on 
top of a CsC1 cushion (5.7 M,  100 mM EDTA). After ultracen- 
trifugation at 150,000 g for 23 h at 18~  the RNA pellet was re- 
suspended in Tris-EDTA (Tris,  10 re_M; EDTA, 5 raM, pH 7.4) 
and precipitated by 3 M sodium acetate and ethanol at -80~  for 
30 man.  Total RNA was extracted from cells and tissues  as de- 
scribed above. Purification ofpoly(A  +) RNA from 10 btg of total 
RNA was performed using the Dynabead mRNA purification kit 
(Dynal, Oslo, Norway). Detection of mRNA by PCR was per- 
formed as described, using a Geneamp RNA PCR kit  (Perkin- 
Elmer Cetus, Uberlingen,  Germany) and a thermocycler (Bach- 
hofer, Reutlingen,  Germany),  according to  the  PCR  protocol. 
DP-1,  ADP-1, and AE2F-2 PCR products were sequenced and 
subsequently  cloned  into  pUHD-3  and pKEX expression plas- 
mids (see below). The following primers were used for amplifica- 
tion: ADP-I: 5' primer, 5'-CCGGAATTCCGGATGGCAAAA- 
GATGCCGGT-3'; 3' primer, 5'-CGCGGATCCGCGCTATTA- 
CAGGTTCTTGAAGGCAAT-3'; AE2F-2:  5' primer, 5'-CCG- 
GAATTCCGGATGCTGCAAGGGCCCCGG-3';  3'  primer, 
5'-CGCGGATCCGCGCTATTACAGAGAGCAGCTCTG- 
GAT-3'; DP-I:  5'  primer,  5'-CCGGAATTCCGGATGGCA- 
AAAGATGCCGGT-3'; 3' primer, 5'-CGCGGATCCGCTCAG- 
TCGTCCTCGTC-3'. 
To  analyze inducible  AE2F-2,  ADP-1,  or DP-1  expression, 
RT-PCR was performed using an upstream primer from the 5' 
transcribed region of the expression plasmid pUHD-3 (5'-CAG- 
ATCGCCTGGAGACGCC-3'; this procedure resulted in frag- 
ment lengths of 784, 790, and 1,315 bp, respectively). [3-actin was 
amplified using the following primers: upstream, 5'-GAGCTG- 
CGTGTGGCTCCCGAGG-3';  downstream,  5'-CGCAGG- 
ATGGCATGGGGGAGGGCATACCCC-3' (resulting  fragment 
length, 246 bp). 
Stable Cell Line HBL- IO0 Expressing Inducible ADp-1 or AE2F-2. 
In the first step, the plasmid pUHD 15-1  (29) containing the tet- 
racycline repressor gene (tet) fused with the viral VP16 coding re- 
gion was linearized with  ScaI, cotransfected with  the  resistance 
plasmAd pUC18  (puromycin resistance;  Boehringer  Mannheim, 
Mannheim, Germany), and selected for stable HBL-100 cell lines. 
Truncated  ADp-1  or  AE2F-2  c-DNA  contained  the  DNA 
binding and dimerization domain of DP-1  (1-235  aa) or E2F-2 
(1-233 aa) but were devoid of the NH2-terminal transactivation 
domain (23, 30--32). Constructs were derived from RT-PCR, se- 
quenced, and cloned into the expression plasmid pUHD 10-3 (29). 
This plasmid was cotransfected with the resistance  plasmid pKEX 
(33) (hygromycin resistance) in a second step into the stable cell lines. 
Modulation  of ADp-1  or AE2F-2 expression was induced by 
incubating the cells in medium in the presence (2 Ixg/ml) or ab- 
sence of tetracycline. In addition, full-length DP-I clones (1-410 
aa) and mock transfectants containing no insert in pUHD  10-3 
were generated by the same protocol. Furthermore, using the ex- 
pression plasmid pKEX, we selected HBL-100 clones, which ex- 
pressed ADp-1 constitutively (ADp-lc). 
Electrophoretic Mobility Shift Assay (EMSA).  Preparation  of nu- 
clear extracts and EMSAs were performed as described (34,  35). 
Briefly, 2.5 p~g of nuclear extract was incubated with 1 ~g ofpoly 
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and  32p-labeled  double-stranded  oligonucleotides  containing a 
binding  site  for  E2F/DP  (5'-ATTTAAGTTTCGCGCCCT- 
TTCTCAA-3') and subsequently analyzed by native PAGE. 
pH]Thymidine Incorporation Assay.  5 ￿  104 cells/well were cul- 
tured in medium in 96-well round-bottom plates at 37~  for 72 h. 
The cells were pulsed with 1 p~Ci of [3H]Thymidine (Amersham, 
Braunschweig, Germany) after 3 d of culture, and DNA synthesis 
was measured during the last 16 h of culture. The cells were har- 
vested  onto  glass filters,  and the  incorporated radioactivity was 
measured using a TopCount counter (Canberra Packard,  Frank- 
furt, Germany). 
Chloramphenicol Acetyl Transferase (CAT) Assay.  CAT  assays 
were performed  using a  reporter plasmid E2F4CAT containing 
the CAT gene under the control of an E2F-dependent promoter 
(36).  Transfection with  20  p~g  of superhelical reporter  plasmid 
DNA per 106 cells in 9-mm culture dishes was carried out by the 
calcium phosphate  coprecipitation technique as described previ- 
ously (37).  At 48 h  after transfection, cellular proteins were  ex- 
tracted  by a  freeze-thaw procedure,  and the  CAT  activity was 
determined as described previously (37). 
Immunocytology.  Immunoperoxidase staining of HBL-100 cells 
was performed using the Vecta stain ABC kit (Vector Laborato- 
ries, Burlingame, CA), according to the manufacturer's protocol. 
Anti-c-myc  mAb was purchased from Dianova (Hamburg,  Ger- 
many); anti-PCNA mouse mAb was purchased from Oncogene 
Science  (Cambridge,  MA).  Polyclonal anti-Ki-67 rabbit  serum 
was purchased from Dako (Hamburg, Germany). 
Determination of Apoptotic Cells by  Acridine Orange Staining. 
Cells were cultured as described above. Apoptosis was induced by 
serum depletion. After induction ofapoptosis, cultures were seeded 
at 3  ￿  105 cells per 1-ml tissue culture well in RPMI 1640, stained 
with acridine orange (5 Ixg/ml), and observed by fluorescence mi- 
croscopy. The number of  fragmented nuclei, which reliably indi- 
cates apoptosis, was determined. 
DNA Fragmentation Assay.  For DNA fragmentation analysis, 
cell lysates  were  obtained by incubating a  cell pellet containing 
10  ~ cells in 20 ml oflysis buffer (10 mM EDTA, 50 mM Tris, pH 
8, 0.5% sarcosyl,  0.5 mg/ml proteinase K) for 1 h  at 50~  After 
addition of 5 ml of RNase (1 mg/ml) and another incubation for 
1  h  at  50~  lysates  were  electrophoresed  on a  2%  agarose  gel 
containing ethidium bromide. The gel was run in a buffer con- 
raining 26 M  Na/HPO  4,  33 mM NaH2PO4,  10 mM EDTA; it 
was photographed under UV illumination. 
Xenotransplantation of Cells into SCID Mice.  HBL-100 cells (106) 
were  injected subcutaneously into  C.B.-17  scid/scid mice.  The 
mice  were  obtained from  our  own  breeding colony and were 
kept in isolators under stringent conditions in the central animal 
laboratory of the Max Delbriick Center for Molecular Medicine. 
Microbiological controls were performed regularly by addition of 
sterile sentinel animals to the colony. Tumors were measured in 
millimeters in two dimensions, length (a) and width (b), using cali- 
pets. Tumor volume (V) was calculated according to  V =  ab2/2, 
where a is the longer of the two measurements. To repress  ADP-1 
expression in vivo, the drinking water was replaced with 2.5% su- 
crose  containing 1.0  mg/ml  tetracycline  hydrochloride  (Sigma 
Chemical Co., St. Louis, MO) as described previously (38). 
Results  and Discussion 
Truncated DP-1  and  E2F-2  Constructs Block Endogenous 
E2F/DP Activity.  To downregnlate endogenous E2F/DP 
activity,  we  designed  DP-1  and  E2F-2  mutants  (ADP-1 
and AE2F-2) that may act in a  dominant-negative manner 
to  functionally inactivate endogenous E2F  activities. Both 
constructs,  ADP-1  and AE2F-2,  contained DNA-binding 
domains  but  were  devoid  of the  transactivation  domain 
(23,  30-32).  By use of a  tetracycline-controlled expression 
system,  the constructs were  expressed  in HBL-100  cells  (a 
nontumorigenic permanent cell line) derived from nonma- 
lignant human  breast  epithelium.  Withdrawal  of tetracy- 
cline led  to  the  induction of ADP-1  or  ~E2F-2  mRNA 
expression which was shown by RT-PCR  (Fig.  1  a).  The 
upstream primer was chosen from the 5' transcribed region 
of the  expression plasmid to  discriminate between exoge- 
nous  and endogenous  ADP-1  or AE2F-2.  We  monitored 
the induction of ADP-1 and AE2F-2 by EMSAs and found 
that both ADP-1  and AE2F-2 competed for DNA  binding 
with  the  endogenous  E2F/DP-1  heterodimer  (Fig.  1  b). 
Tetracycline withdrawal led to  complete  disappearance  of 
the endogenous E2F/DP  binding complex, which was re- 
Figure 1,  Inducible expression of ADP-1 or AE2F-2 in HBL-100 cells. 
(a) Stable clones, which are under transcriptional control of a tetracycline 
(tet)-dependent  transactivator, were  generated, as described in Materials 
and Methods.  HBL-100  clones transfected with either  truncated  DP-1 
(ZIDP-1), truncated  E2F-2 (AE2F-2), or full-length DP-1  (DP-I) were 
analyzed by RT-PCK. The upstream  primer was  chosen  from  the 5' 
transcribed region of the expression plasmid to discriminate between ex- 
ogenous and endogenous DP-1. The resulting fragment lengths are indi- 
cated. Cells were cultured in the presence (+) or absence (-) of tetracy- 
cline. RNA was extracted 24 h after tetracycline withdrawal. Induction  of 
ADP-1, AE2F-2, and DP-1 expression can be detected after tetracycline 
withdrawal, whereas in the presence of tetracycline, expression is com- 
pletely repressed. 13-Actin and mock transfectants served as controls.  (b) 
Nuclear E2F/DP-binding  complexes of inducible and constitutive HBL- 
100 clones. The same clones as in a and one constitutive  ADP-1  clone 
(ADP-lc) were analyzed by EMSA. Where indicated, a 50-M excess of 
unlabeled  binding oligonucleotide  was  added  to  show  specificity  of 
DNA-binding  complexes. Cells were cultured in the presence (+) or ab- 
sence (-) of tetracycline. Nuclear protein was extracted 24 h after tetra- 
cycline withdrawal. Induction of ADP-1  or AE2F-2 expression leads to 
complete  disappearance of the  endogenous  E2F/DP binding complex, 
which is replaced by a  smaller complex.  Full-length  DP-1  and mock 
transfectants served as controls. 
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tained  the  truncated  mutants.  To  test  whether  truncated 
DP-1  or  truncated  E2F-2  inhibits  E2F-dependent  tran- 
scriptional activity, we transfected reporter genes under the 
control  of an  E2F-dependent  promoter  into  ADP-1  and 
AE2F-2 clones of HBL-100. As depicted in Fig. 2  a, strongly 
decreased  CAT  activity could be  observed after induction 
of either ADP-1  or AE2F-2. 
Using immunocytological staining, we were  also able to 
show that induction of ADpl  led to strong downregulation 
of endogenous c-myc  (Fig. 2  b), which contains E2F-bind- 
ing sites in its promoter and has been described as a  target 
gene of E2F/DP  (39).  The same result was observed using 
the  E2F-2  mutant  (not  shown).  Expression  of Ki-67,  a 
marker indicating that the cycling state of cells, was not af- 
fected by the  induction of ADp-1  (Fig.  2  b).  Thus,  trun- 
cated  DP-1  or  E2F-2  blocked  E2F/DP-dependent  tran- 
scriptional activity, which was consistent with the complete 
disappearance of endogenous E2F7DP binding complex in 
EMSAs  (see  Fig.  1).  From these  results,  we  conclude that 
our  truncated  constructs  are  dominant-negative  mutants 
that are able to block E2F/DP. 
Blocking of Endogenous E2F/DP Activity Does Not Alter the 
Proliferation Rate of HBL-IO0 Cells.  E2F  is thought  to  act 
Figure  2.  Downregulation of E2F-dependent promoter  activity  in 
ADP-1 or AE2F-2 expressing HBL-100 cells. (a) Repression of CAT ac- 
tivity. Transcriptional activity of endogenous E2F was analyzed in induc- 
ible HBL-100 clones, using a reporter construct under the control of an 
E2F-dependent promoter. Cells were cultured in the presence (+) or ab- 
sence (-) of tetracycline. CAT assays were performed 24 h after tetracy- 
cline withdrawal,  as described in Materials and Methods.  Induction of 
ADP-1  or AE2F-2 expression leads to  strong  downregulation  of E2F- 
dependent promoter activity. Induction of  full-length DP-1 does not alter 
CAT activity. Mock transfectants served as controls. (b) Downregulation 
of endogenous c-myc  expression. Expression of endogenous c-myc  protein 
was  analyzed in inducible  ADP-1  clones by immunocytology,  as  de- 
scribed in Materials and Methods. Where indicated, cells were cultured in 
the presence  (+)  or absence (-)  of tetracycline.  Cells were  fixed and 
stained with an indirect immunoperoxidase method 24 h after tetracycline 
withdrawal. Induction of ADP-1 expression leads to strong downregula- 
tion of c-myc expression in HBL-100  cells, whereas expression of Ki-67 
remained unaffected in these cells. Mock transfectants served as control. 
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E2F-mediated transcriptional activation includes genes that 
are important for S phase progression;  therefore,  E2F may 
be  one  of the  rate-limiting  steps  in  cell  proliferation.  For 
this reason, we were interested to find out whether expres- 
sion of the dominant-negative E2F/DP mutants would in- 
fluence proliferation and DNA synthesis. Surprisingly, block- 
ing of E2F did not alter the proliferation rate or the DNA 
synthesis rate of HBL-100 cells  (Fig. 3). These results are in 
contrast to the biological effect of similar dominant-nega- 
tive  E2F  mutants  described  in  quiescent  3T3  fibroblasts 
(40).  In these cells,  a AE2F mutant blocked cell cycle pro- 
gression induced by the adenovirus protein E1A. EIA acts 
via the E2F pathway by liberating E2F from multicompo- 
nent complexes that contain the product of the retinoblas- 
toma gene, pRb, and related proteins.  In the fibroblasts, cell 
cycle progression is E2F-dependent and could therefore be 
blocked by E2F dominant-negative mutants.  Although we 
can  not  exclude  the  possibility  that  unaffected  cell  cycle 
progression in HBL-100 cells  expressing  either  ADP-1  or 
AE2F-2 could be due to incomplete suppression of endog- 
enous E2F activity, we propose that cell cycle progression 
and transcription of  important S phase genes could be driven 
in an E2F-independent manner. This hypothesis is supported 
by our observation that PCNA, an important cell cycle regu- 
lating S phase protein, which is another potential target gene 
of  E2F, was not affected by our dominant-negative mutants 
(not shown).  Therefore,  it seems  that some  (naturally  oc- 
curring)  E2F-responsive promoters  can be  downregulated 
(c-myc) by such mutants but others cannot be (PCNA). 
Blocking of Endogenous E2F/DP Activity Inhibits Induction 
of Apoptosis.  Next we wanted to know whether blocking 
of endogenous E2F alters  sensitivity toward apoptosis. We 
therefore induced apoptosis by serum  depletion  and asked 
whether the expression of either ADP-1 or AE2F-2 would 
affect  apoptosis.  Our  results  show  that  after  induction  of 
ADP-1  or  AE2F-2,  apoptosis  could  be  blocked  for  10  d 
(Fig.  4).  In  contrast,  in  the  presence  of tetracychne,  our 
Figure 3.  Proliferation  rate of ADP-1- or AE2F-2-expressing  HBL-100 cells. Cells were cultured in the presence (+) or absence (-) of  tetracycline. 
(a and b) Number of  viable cells was determined on days 1, 2, 4, 8, and 10 after withdrawal of  tetracycline. Viability  was determined by trypan blue stain- 
ing. Mean values and SD of four independently performed experiments are indicated. (c) [3H]Thymidine  incorporation was measured 3 d after with- 
drawal of tetracycline. Again, mean values and SD of four independently performed experiments are indicated. Mock transfectants served as the control. 
Induction of ADP-1 or AE2F-2 expression in HBL-IO0 cells has no effect on the rate of  DNA synthesis or cell proliferation. 
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ter  1  d  of serum starvation.  Therefore,  it appears that in- 
duction of apoptosis by growth factor depletion in cycling 
ceils was  at  least  in  part  mediated by  an  E2F-dependent 
pathway.  This concept is in accord with previous findings 
that  in  vivo  overexpression of exogenous  E2F-1  induced 
apoptosis  in  fibroblasts  (25-28).  It  has  been  shown  that 
constitutive  c-myc  expression  causes  apoptosis  in  serum- 
starved cells (11). We have shown that blocking of endoge- 
nous E2F led to downregulation of endogenous c-myc ex- 
pression and inhibition of apoptosis. Therefore, one might 
speculate that E2F-dependent apoptosis could be regulated 
at least in part by transcription of the c-myc gene. Our find- 
ings  are  strengthened  by  the  fact  that  the  retinoblastoma 
gene product,  an important regulator of E2F,  also inhibits 
apoptosis (13). 
Thus,  E2F/DP  is a  transcription factor involved in  the 
regulation of two  different biological processes and there- 
fore provides another example of the close linkage between 
apoptosis and control of the cell cycle. 
Blocking of Endogenous E2F/DP Activity  in Normal Breast 
Epithelial Cell Line HBL-I O0 Induces Tumor Growth in SCID 
Mice.  We  recently provided evidence  that  dysregulation 
of apoptosis might be an important step in the pathogenesis 
of breast cancer  (9).  Therefore,  we were interested in de- 
termining  whether  enhanced  resistance  to  apoptosis  of 
Figure 4.  Inhibition of serum starvation-induced apoptosis in ADP-1 or AE2F-2 expressing  HBL-100 cells. Cells of soluble ADP-1 or &E2F-2 clones 
or constitutive ADP-1 clones (ADP-lc) were cultured in the presence or absence of tetracycline (+/- Tet) for prolonged time periods after serum star- 
vation. (a and b) Apoptosis was assayed  morphologically  by staining the nuclei with acridine orange on days 1-10. The number of fragmented nuclei (in- 
dicating apoptosis)  from 100 cells  was determined and is expressed  as a percentage ofapoptotic cells.  The mean SD of four independent experiments is in- 
dicated. Induction of ADP-1 or AE2F-2 efficiently  protects from apoptosis in HBL-100 cells within the observed period of 10 d. In contrast, repression 
of either ADP-1 or AE2F-2 expression led to induction of apoptosis after serum starvation for 2 d. In constitutively expressing cells, tetracycline has no 
effect on apoptosis resistance.  Inducible full-length DP-l-expressing cells (DP-I) served as control. (c) Detection of apoptosis by DNA fragmentation in 
ADP-l-expressing  HBL-100 cells.  Agarose gel electrophoresis  of  DNA extracted from constitutive or inducible ADP-1 clones 2 d after serum depletion. 
DNA fragmentation can be observed only when ADP-1 expression is repressed.  No DNA fragmentation can be observed in ADP-l-expressing  cells. 
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nicity. We transplanted ADP-1 and mock-transfected HBL- 
100  cells into SCID mice. To suppress ADP-1  or AE2F-2 
expression in vivo, tetracycline was  added to  the  animals' 
drinking water.  As depicted in Fig.  5,  tumor  growth was 
observed  only  in  animals  that  carried  either  ADP-1-  or 
AE2F-2-expressing cells and obtained no tetracycline from 
their  drinking water.  No  tumor  growth  was  observed in 
animals that were  challenged with HBL-100  cells but that 
did not express truncated mutants. Therefore, we conclude 
that blocking of endogenous E2F activity can induce tumor 
growth in SCID mice and that this induction is most likely 
due to an enhanced resistance to apoptosis. It appears that, 
in cells proliferating in an E2F-independent manner,  E2F 
has a potential tumor-suppressive function. Recently, it has 
been reported that induction of apoptosis in E2F-overex- 
pressing cells depends  on  the  expression of p53  (27,  28). 
Therefore, it will be interesting to look for loss of function 
mutations  of  the  E2F/DP  family,  particularly  in  p53- 
expressing tumors. Thus, we provide further evidence that 
dysregulation of apoptosis is an  important step in tumori- 
genesis. 
In conclusion, we found that downregulation of endog- 
enous E2F/DP activity did not affect the proliferation rate 
of the breast epithelial cell line HBL-100 but led to down- 
regulation of c-myc expression, enhanced resistance toward 
apoptosis, and  induction of tumorigenic growth  in  SCID 
mice. Therefore, we propose the following three hypoth- 
eses.  First,  cell  cycle  progression  can  be  driven  in  an 
E2F independent manner.  Second, endogenous E2F is in- 
volved  in  the  regulation  of apoptosis  (possibly via tran- 
scriptional  regulation  of c-myc expression).  Third,  under 
certain circumstances, E2F  has a  potential tumor-suppres- 
sive function. 
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Figure 5.  Tumor growth of ADP-1- or AE2F- 
2-expressing  HLB-100  cells in  SCID  mice. 
Shown is tumor growth of inducible (a) ADP-1, 
(b) AE2F-2, or constitutive ADP-l-expressing  (a) 
ADP-lc HBL-100 clones in SCID mice. Ammals 
were challenged with the same cell number (106); 
where  indicated,  tetracycline  (1  mg/ml)  was 
added to the drinking water to suppress ADP-1 
expression in vivo. Mean values and SD of the 
tumor size of 10 animals are indicated. Expression 
of ADP-1 or AE2F-2 leads to rapid induction of 
tumor growth, whereas tetracycline repression of 
the mutants prevents tumor growth. Since tetra- 
cycline does not affect tumor growth of constitu- 
tively  expressing clones, suppression of tumor 
growth of inducible clones is not due to a toxic 
effect of tetracycline. Animals challenged with 
mock-transfected  or  nontransfected  clones did 
not show tumor growth (not shown). Address  correspondence to Dr.  Ralf C. Bargou, Max Delbriick Center for Molecular Medicine, Robert 
R6ssle Str. 10, 13122 Berlin-Buch, Germany. 
Received for publication  5July  1995 and in revised  form 2I November  1995. 
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